Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vistagen Therapeutics Announces Publications Supporting the Use of Embryonic Stem Cells

Published: Thursday, December 28, 2006
Last Updated: Thursday, December 28, 2006
Bookmark and Share
The publications highlight advances to understand how embryonic stem cells can be reproducibly differentiated into heart and liver cells.

VistaGen Therapeutics, Inc. has announced three recent publications highlighting important advances in the understanding of how embryonic stem cells can be reproducibly differentiated into heart and liver cells.

According to VistaGen, these advances are a result of the research efforts directed by Dr. Gordon Keller, a highly regarded international stem cell scientist, Director of the McEwen Center for Regenerative Medicine in Toronto and Chairman of VistaGen’s Scientific Advisory Board.

VistaGen has an exclusive license to these stem cell technologies for all pharmaceutical drug discovery and screening applications.

In the three recent publications in Nature BiotechnologyProceeding of the National Academy of Sciences, and Developmental Cell, Dr. Keller’s laboratory announced advancements in the understanding of how to induce and control the differentiation of embryonic stem cells into important immature endoderm cells that ultimately go on to form the internal organs of the body, especially the liver and heart.

These publications can also expand the understanding of the culture conditions necessary to generate large populations of cells which have functional properties of liver and heart cells.

"My team’s efforts represent important building blocks we need to begin to develop new tools for multiple medical applications of ES cells, including drug discovery and screening for the treatment of diseases of the cardiovascular system and liver," said Dr. Keller.

Dr. Ralph Snodgrass, VistaGen’s President and CEO, added, "We are very encouraged by the advancements made by Dr. Keller's research, and are excited to work in concert with him to develop reproducible and powerful biological systems that will open new approaches in the field of predictive toxicology assays involving the two most important target organs, the heart and liver, as well as new opportunities for drug discovery, especially in diabetes."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VistaGen Secures Key U.S. Stem Cell Technology Patent
United States patent covers the company's proprietary methods used to measure and type the toxic effects produced by drug compounds in liver stem cells.
Thursday, April 26, 2012
VistaGen Increases Its Drug Rescue Opportunities
Long-term relationship with global contract research and development organization expands to include right-of-first-offer for potential drug rescue candidates.
Thursday, February 09, 2012
VistaGen Therapeutics and University Health Network Extend Collaborative Stem Cell Research
Alliance Supports Drug Rescue Initiatives, Cell Therapy Applications, and Focus on Large-Scale Production of Stem Cells
Thursday, November 17, 2011
VistaGen Therapeutics Reports Advances in its Pancreatic Cell and Regenerative Medicine Programs
Use of pluripotent stem cells to generate insulin in mice.
Tuesday, September 27, 2011
VistaGen Therapeutics Provides Investor Update on Corporate Activities and Upcoming Initiatives
VistaGen provides comprehensive update on the Company's strategic plan to develop and commercialize its technology platform and lead small molecule CNS drug candidate.
Friday, September 16, 2011
Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!